Your browser is no longer supported. Please, upgrade your browser.
Esperion Therapeutics, Inc.
Index- P/E- EPS (ttm)-12.12 Insider Own17.00% Shs Outstand28.19M Perf Week-3.83%
Market Cap252.89M Forward P/E- EPS next Y-6.27 Insider Trans9.64% Shs Float26.26M Perf Month-27.36%
Income-324.50M PEG- EPS next Q-2.79 Inst Own- Short Float27.89% Perf Quarter-42.96%
Sales62.10M P/S4.07 EPS this Y-45.70% Inst Trans0.02% Short Ratio8.76 Perf Half Y-69.36%
Book/sh-11.60 P/B- EPS next Y51.90% ROA-111.60% Target Price- Perf Year-72.40%
Cash/sh- P/C- EPS next 5Y16.90% ROE196.40% 52W Range8.37 - 39.49 Perf YTD-66.19%
Dividend- P/FCF- EPS past 5Y-18.20% ROI-145.70% 52W High-77.74% Beta1.01
Dividend %- Quick Ratio3.00 Sales past 5Y- Gross Margin91.10% 52W Low5.02% ATR0.66
Employees479 Current Ratio3.30 Sales Q/Q-80.80% Oper. Margin- RSI (14)30.25 Volatility7.50% 6.28%
OptionableYes Debt/Eq- EPS Q/Q-138.60% Profit Margin- Rel Volume0.70 Prev Close8.97
ShortableYes LT Debt/Eq- EarningsNov 02 BMO Payout- Avg Volume835.91K Price8.79
Recom2.50 SMA20-17.03% SMA50-26.33% SMA200-59.25% Volume583,675 Change-2.01%
Oct-19-21Downgrade Credit Suisse Outperform → Neutral $28 → $11
Oct-14-21Downgrade Morgan Stanley Equal-Weight → Underweight $17 → $11
May-05-21Downgrade Stifel Buy → Hold $37 → $20
Apr-26-21Resumed Credit Suisse Outperform $45
Mar-11-21Initiated Morgan Stanley Equal-Weight $30
Feb-12-21Downgrade Jefferies Buy → Hold $30
Feb-09-21Downgrade Goldman Neutral → Sell $44 → $24
Jan-15-21Downgrade BofA Securities Buy → Neutral $52 → $35
Nov-10-20Upgrade Credit Suisse Neutral → Outperform $45
Sep-29-20Resumed JP Morgan Underweight $35
Aug-11-20Downgrade Credit Suisse Outperform → Neutral $83 → $45
Apr-01-20Resumed BofA/Merrill Buy $50
Mar-17-20Upgrade Citigroup Neutral → Buy
Feb-24-20Downgrade Northland Capital Outperform → Market Perform $60
Feb-14-20Downgrade Citigroup Buy → Neutral $82
Sep-16-19Upgrade Goldman Sell → Neutral $55 → $45
May-29-19Downgrade Goldman Neutral → Sell
May-06-19Upgrade BofA/Merrill Underperform → Neutral
Apr-26-19Upgrade Goldman Sell → Neutral $50
Mar-13-19Upgrade JP Morgan Underweight → Neutral $38 → $47
Oct-19-21 10:43AM  
Oct-18-21 05:54PM  
Oct-12-21 08:00AM  
Sep-24-21 09:33AM  
Sep-09-21 10:50AM  
Sep-08-21 12:40PM  
Sep-07-21 04:01PM  
Sep-02-21 11:31AM  
Aug-26-21 08:00AM  
Aug-08-21 05:48AM  
Aug-04-21 10:25AM  
Aug-03-21 08:00PM  
Aug-02-21 01:07PM  
Jul-30-21 11:46AM  
Jul-27-21 03:03PM  
Jul-13-21 08:00AM  
Jul-01-21 05:00PM  
Jun-28-21 07:59AM  
Jun-03-21 11:31AM  
May-24-21 08:00AM  
May-17-21 09:01AM  
May-15-21 12:00PM  
May-09-21 03:42AM  
May-06-21 08:00AM  
May-05-21 06:30PM  
May-04-21 09:00PM  
Apr-28-21 04:05PM  
Apr-27-21 08:00AM  
Apr-26-21 04:07PM  
Apr-12-21 04:01PM  
Apr-06-21 08:00AM  
Apr-02-21 10:27AM  
Mar-25-21 11:30AM  
Mar-17-21 04:05PM  
Feb-26-21 11:55AM  
Feb-24-21 03:02AM  
Feb-23-21 05:15PM  
Feb-17-21 02:25AM  
Feb-09-21 08:00AM  
Feb-03-21 11:49AM  
Jan-29-21 05:21PM  
Jan-14-21 10:36AM  
Jan-13-21 01:21PM  
Jan-04-21 11:53AM  
Dec-21-20 08:00AM  
Dec-19-20 02:45AM  
Dec-16-20 05:34PM  
Dec-15-20 07:00AM  
Dec-02-20 12:37PM  
Nov-13-20 09:15AM  
Nov-12-20 06:17AM  
Nov-10-20 04:30PM  
Nov-06-20 05:00PM  
Nov-04-20 06:15AM  
Nov-03-20 09:36AM  
Nov-02-20 11:31PM  
Oct-27-20 08:00AM  
Oct-26-20 12:31PM  
Oct-19-20 08:00AM  
Oct-13-20 03:04PM  
Oct-07-20 08:00AM  
Sep-28-20 04:06PM  
Sep-22-20 08:56AM  
Sep-02-20 08:41AM  
Aug-26-20 09:07AM  
Aug-21-20 04:05PM  
Aug-11-20 11:10AM  
Aug-10-20 05:15PM  
Aug-07-20 09:27AM  
Aug-06-20 10:05AM  
Aug-03-20 07:26AM  
Jul-16-20 07:16PM  
Jul-01-20 11:12AM  
Jun-23-20 11:42AM  
Jun-22-20 07:00AM  
Jun-16-20 03:09PM  
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low-density lipoprotein cholesterol in the United States and internationally. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BIOTECH TARGET N V10% OwnerMay 19Buy20.37200,0004,073,9604,377,964May 21 02:06 PM
BIOTECH TARGET N V10% OwnerMay 06Buy20.5780,0001,645,6324,177,964May 07 03:23 PM
BIOTECH TARGET N V10% OwnerMay 05Buy20.02150,0003,002,8504,097,964May 07 03:23 PM
MAYLEBEN TIMOTHY MPresident & CEODec 30Option Exercise2.1010,70022,427122,698Dec 31 04:09 PM
BIOTECH TARGET N V10% OwnerNov 03Buy25.31200,0005,062,1203,947,964Nov 04 04:37 PM